Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia

por Shore, Neal, Tutrone, Ronald, Roehrborn, Claus G.
Publicado 2019

Second Reply to Letter to the Editor re: “Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting”

por White, Jay, Tutrone, Ronald F., Reynolds, Mark A.
Publicado 2019

Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-...

por Haas, Naomi B, Stein, Mark N, Tutrone, Ronald, Perini, Rodolfo, Denker, Andrew, Mauro, David, Fong, Lawrence
Publicado 2015

Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2–10 ng/mL

por Tutrone, Ronald, Donovan, Michael J., Torkler, Phillipp, Tadigotla, Vasisht, McLain, Tom, Noerholm, Mikkel, Skog, Johan, McKiernan, James
Publicado 2020

Prostatic Urethral Lift (PUL) for obstructive median lobes: 12 month results of the MedLift Study

por Rukstalis, Daniel, Grier, Douglas, Stroup, Sean P., Tutrone, Ronald, deSouza, Euclid, Freedman, Sheldon, David, Richard, Kamientsky, Jed, Eure, Gregg
Publicado 2018

ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study

por Stein, Mark N, Fong, Lawrence, Tutrone, Ronald, Mega, Anthony, Lam, Elaine T, Parsi, Megan, Vangala, Surya, Gutierrez, Andres A, Haas, Naomi B
Publicado 2022

Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer

por Shore, Neal D., Mehlhaff, Bryan A., Cookson, Michael S., Saltzstein, Daniel R., Tutrone, Ronald, Brown, Bruce, Lu, Sophia, Fallick, Mark, Hanson, Sarah, Saad, Fred
Publicado 2023

Pre-diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post-prostatectomy pathology outcome

por Kretschmer, Alexander, Tutrone, Ronald, Alter, Jason, Berg, Elena, Fischer, Christian, Kumar, Sonia, Torkler, Phillipp, Tadigotla, Vasisht, Donovan, Michael, Sant, Grannum, Skog, Johan, Noerholm, Mikkel
Publicado 2022

A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer

por De La Cerda, Jose, Dunshee, Curtis, Gervasi, Lawrence, Sieber, Paul, Belkoff, Laurence, Tutrone, Ronald, Lu, Sophia, Gatoulis, Sergio C., Brown, Bruce, Migoya, Elizabeth, Shore, Neal
Publicado 2023

Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer

por Saad, Fred, George, Daniel J., Cookson, Michael S., Saltzstein, Daniel R., Tutrone, Ronald, Bossi, Alberto, Brown, Bruce, Selby, Bryan, Lu, Sophia, Tombal, Bertrand, Shore, Neal D.
Publicado 2023

Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results

por Shore, Neal, Kaplan, Steven A., Tutrone, Ronald, Levin, Richard, Bailen, James, Hay, Alan, Kalota, Susan, Bidair, Mohamed, Freedman, Sheldon, Goldberg, Kenneth, Snoy, Frederick, Epstein, Jonathan I.
Publicado 2020

Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies

por Margolis, Erik, Brown, Gordon, Partin, Alan, Carter, Ballentine, McKiernan, James, Tutrone, Ronald, Torkler, Phillipp, Fischer, Christian, Tadigotla, Vasisht, Noerholm, Mikkel, Donovan, Michael J., Skog, Johan
Publicado 2021

ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis

por Tutrone, Ronald, Lowentritt, Ben, Neuman, Brian, Donovan, Michael J., Hallmark, Elliot, Cole, T. Jeffrey, Yao, Yiyuan, Biesecker, Claire, Kumar, Sonia, Verma, Vinita, Sant, Grannum R., Alter, Jason, Skog, Johan
Publicado 2023

Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results

por Chi, Kim N, Fleshner, Neil, Chiuri, Vincenzo Emanuele, Van Bruwaene, Siska, Hafron, Jason, McNeel, Douglas G, De Porre, Peter, Maul, Raymond Scott, Daksh, Mahesh, Zhong, Xiaogang, Mason, Gary E, Tutrone, Ronald F
Publicado 2023

Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting

por White, Jay, Shenoy, B. Vittal, Tutrone, Ronald F., Karsh, Lawrence I., Saltzstein, Daniel R., Harmon, William J., Broyles, Dennis L., Roddy, Tamra E., Lofaro, Lori R., Paoli, Carly J., Denham, Dwight, Reynolds, Mark A.
Publicado 2017

Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement

por Shore, Neal, Tutrone, Ronald, Efros, Mitchell, Bidair, Mohamed, Wachs, Barton, Kalota, Susan, Freedman, Sheldon, Bailen, James, Levin, Richard, Richardson, Stephen, Kaminetsky, Jed, Snyder, Jeffrey, Shepard, Barry, Goldberg, Kenneth, Hay, Alan, Gange, Steven, Grunberger, Ivan
Publicado 2018

Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men

por Waterhouse, Robert L., Van Neste, Leander, Moses, Kelvin A., Barnswell, Carlton, Silberstein, Jonathan L., Jalkut, Mark, Tutrone, Ronald, Sylora, James, Anglade, Ronald, Murdock, Myron, Shiffman, Zvi, Vandenberg, Todd, Shah, Nikhil, Carter, Michael, Krispin, Manuel, Groskopf, Jack, Van Criekinge, Wim
Publicado 2019

Validation of a CE-IVD, urine exosomal RNA expression assay for risk assessment of prostate cancer prior to biopsy

por Kretschmer, Alexander, Kajau, Holger, Margolis, Eric, Tutrone, Ronald, Grimm, Tobias, Trottmann, Matthias, Stief, Christian, Stoll, Georg, Fischer, Christian A., Flinspach, Claudia, Albrecht, Anja, Meyer, Lisa, Priewasser, Tina, Enderle, Daniel, Müller, Romy, Torkler, Phillipp, Alter, Jason, Skog, Johan, Noerholm, Mikkel
Publicado 2022

Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer

por Higano, Celestia S., Armstrong, Andrew J., Sartor, A. Oliver, Vogelzang, Nicholas J., Kantoff, Philip W., McLeod, David G., Pieczonka, Christopher M., Penson, David F., Shore, Neal D., Vacirca, Jeffrey, Concepcion, Raoul S., Tutrone, Ronald F., Nordquist, Luke T., Quinn, David I., Kassabian, Vahan, Scholz, Mark C., Harmon, Matt, Tyler, Robert C., Chang, Nancy N., Tang, Hong, Cooperberg, Matthew R.
Publicado 2019

Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry

por Sartor, Oliver, Armstrong, Andrew J., Ahaghotu, Chiledum, McLeod, David G., Cooperberg, Matthew R., Penson, David F., Kantoff, Philip W., Vogelzang, Nicholas J., Hussain, Arif, Pieczonka, Christopher M., Shore, Neal D., Quinn, David I., Small, Eric J., Heath, Elisabeth I., Tutrone, Ronald F., Schellhammer, Paul F., Harmon, Matthew, Chang, Nancy N., Sheikh, Nadeem A., Brown, Bruce, Freedland, Stephen J., Higano, Celestia S.
Publicado 2020